Pancreatic Cancer Research

ResearcherShandong UniversityActive in the last 2 years

Xinxing Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1650-3297; OpenAlex author ID A5100740799. Sources: OpenAlex.

Their work

Papers
6
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 6

  1. TWIST1 regulates HK2 ubiquitination degradation to promote pancreatic cancer invasion and metastasis. Co-author DOI 10.1186/s12935-024-03583-z↗
  2. Knockdown of TGF-β in Pancreatic Cancer Helps Ameliorate Gemcitabine Resistance. Co-author DOI 10.31083/j.fbl2907269↗
  3. miR-30d suppresses proliferation and invasiveness of pancreatic cancer by targeting the SOX4/PI3K-AKT axis and predicts poor outcome. Co-author DOI 10.1038/s41419-021-03576-0↗
  4. [Corrigendum] Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ijo.2020.5157↗
  5. TWIST1 transcriptionally regulates glycolytic genes to promote the Warburg metabolism in pancreatic cancer. Co-author DOI 10.1016/j.yexcr.2019.111713↗
  6. Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ijo.2017.4099↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhenhai Zhang · 5 shared papers, 2017–2025 · strength 0.84
  2. Guozhe Xian · 3 shared papers, 2017–2021 · strength 0.33
  3. Zhiyi Wang · 3 shared papers, 2017–2021 · strength 0.33
  4. Junlin Gao · 1 shared paper, 2024 · strength 0.23
  5. Chengkun Qin · 2 shared papers, 2017–2021 · strength 0.21
  6. Xianping Cui · 2 shared papers, 2017–2021 · strength 0.21
  7. Xiaodong Xu · 1 shared paper, 2021 · strength 0.15
  8. Hongwen Li · 1 shared paper, 2021 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.